Dendritic Cell-Based Immunotherapy of Malignant Gliomas

References

• Steinman R. M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001; 94: 459–473, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brossart P., Wirths S., Brugger W., Kanz L. Dendritic cells in cancer vaccines. Exp. Hematol. 2001; 29: 1247–1255, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sprinzl G. M., Kacani L., Schrott-Fischer A., Romani N., Thumfart W. F. Dendritic cell vaccines for cancer therapy. Cancer Treat. Rev. 2001; 27: 247–255, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhou L.-J., Tedder T. F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 1995; 154: 3821–3835, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• de Saint-Vis B., Vincent J., Vandenabeele S., Vanbervliet B., Pin J. J., Ait-Yahia S., Patel S., Mattei M. G., Banchereau J., Zurawski S., Davoust J., Caux C., Lebecque S. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998; 9: 325–336, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sallusto F., Cella M., Danieli C., Aanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macro-molecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial roducts. J. Exp. Med. 1995; 182: 389–400, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fanger N. A., Wardwell K., Shen L., Tedder T. F., Guyre P. M. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 1996; 157: 541–548, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Arnold-Schild D., Hanau D., Spehner D., Schmid C., Rammcnsee H. G., de la Salle H., Schild H. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 1999; 162: 3757
   PubMed Web of Science ®Google Scholar
• Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1999; 1: 362–368, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol. 1997; 15: 821–850, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sauter B., Albert M. L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 2000; 191: 423–434, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Albert M. L., Sauter B., Bhardwaj. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86–89, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Albert M. L., Jegathesan M., Darnell R. B. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat. Immunol. 2001; 2(11)1010–1017, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schoenberger S. P., Toes R. E., van der Voort E. I., Offringa R., Melief C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480–483, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bennett S. R., Carbone F. R., Karamalis F., Flavell R. A., Miller J. F., Heath W. R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478–480, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M., Banchereau J., Fay J., Palucka K. Dendritic cell based tumor vaccines. Immunol. Lett. 2000; 74: 5–10, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McLendon R. E., Wikstrand C. J., Matthews M. R., Al-Baradei R., Bigner S. H., Bigner D. D. Glioma-associated antigen expression in oligodendroglial neoplasms: tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000; 48: 1103–1110, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kuan C. T., Wikstrand C. J., Bigner D. D. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathology 2000; 17: 71–78, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Chakravarty A., Delaney M. A., Noll E., Black P. N., Loeffler J. S., Muzikansky A., Dyson N. J. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin. Cancer Res. 2001; 7: 2387–2395, [CSA]
   PubMed Web of Science ®Google Scholar
• Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr. Opin. Mol. Ther. 1999; 1: 500–509, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pollack I. F., Finkelstein S. D., Woods J., Burnham J., Holmes E. J., Hamilton R. L., Yates A. J., Boyett J. M., Finlay J. L. Expression of p53 and prognosis in children with maliognant gliomas. N. Engl. J. Med. 2002; 346: 420–427, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Scarcella D. L., Chow C. W., Gonzales M. F., Economou C., Brasseur F., Ashley D. M. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin. Cancer Res. 1999; 5: 335–341, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Imaizumi T., Kuramoto T., Matsunaga K., Shichijo S., Yutani S., Shigemori M., Oizumi K., Itoh K. Expression of the tumor rejection antigen SART1 in brain tumors. Int. J. Cancer 1999; 83: 760–764, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Murayama K., Kobayashi T., Imaizumi T., Matsunaga K., Kuramoto T., Shigemori M., Shichijo S., Itoh K. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J. Immunother. 2000; 23: 511, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sahin U., Koslowski M., Tureci O., Eberle T., Zwick C., Romeike B., Moringlane J. R., Schwechheimer K., Feiden W., Pfreundschuh M. Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 2000; 6: 3916–3922, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Loging W. T., Lal A., Siu I.-M., Loney T. L., Wikstrand C. J., Marra M. A., Prange C., Bigner D. D., Strausberg R. L., Riggins G. J. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res. 2000; 10: 1393–1402, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sallinen S.-L., Sallinen P. K., Haapasalo H. K., Helin H. J., Helen P. T., Schraml P., Kallioniemi O. P., Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000; 60: 6617–6622, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schmits R., Cochlovius B., Treiz G., Regitz E., Ketter R., Preuss K., Romeike B. F., Pfreundschuh M. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int. J. Cancer 2002; 98: 73–77, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fischer U., Struss A. K., Hemmer D., Pallasch C. P., Steudel W. I., Meese E. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin. Exp. Immunol 2001; 126: 206–213, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Albert M. L., Sauter B., Bhardwaj N. Dendritic cells acquire antigens from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86–89, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jenne L., Arright J., Jonuleit H., Saurat J. H., Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000; 60: 4446–4452, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Siesjo P., Visse E., Sjogren H. O. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment. J. Immunother. 1996; 19: 334–345, [CSA]
   PubMed Web of Science ®Google Scholar
• Heimberger A. B., Crotty L. E., Archer G. E., McLendon R. E., Friedman A., Dranoff G., Bigner D. D., Sampson J. H. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J. Neuroimmunol. 2000; 103: 16–25, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aoki H., Mizuo M., Natsume A., Tsugawa T., Tsujimura K., Takahashi T., Yoshida J. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol. Immunother. 2001; 50: 463–468, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ni H., Speliman S. R., Jean W. C., Hall W. A., Low W. C. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracerebral gliomas. J. Neuro-Oncol. 2001; 51: 1–9, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liau L. M., Black K. L., Prins R. M., Sykes S. N., DiPatre P.-L., Cloughesy T. F., Becker D. P., Bronstein J. M. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 1999; 90: 1115–1124, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Boczkowski D., Nair S. K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996; 184: 465–472, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11: 263–270, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ashley D. M., Faiola B., Nair S., Hale L. P., Bigner D. D., Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 1997; 186: 1177–1182, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yamanaka R., Zullo S. A., Tanaka R., Blaese M., Xanthopoulos K. G. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semiliki Forest virus-mediated complementary DNA. J. Neurosurg. 2001; 94: 474–481, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Akasaki Y., Kikuchi T., Homma S., Abe T., Kofe D., Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 2001; 24: 106–113, [CROSSREF]
   Web of Science ®Google Scholar
• Kotera Y., Shimizu K., Mule J. J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001; 61: 8105–8109, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sloan A. E., Parajuli P. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity. J. Neuro-Oncology. 2003; 64: 177–183, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sloan A. E., Parajuli P., Mathupala S. P. DC-tumor cell fusion for induction of tumor-specific T-cell response against malignant brain tumors: comparison with DC pulsed with total tumor RNA or tumor lysate. Proc. Am. Assoc. Cancer Res. 2002; 93, Abstract 476
   Google Scholar
• Yamanaka R., Zullo S. A., Ramsey J., Yajima N., Tsuchiya N., Tanaka R., Blaese M., Xanthopoulos K. G. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 2002; 97: 611–618, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Liau L. M., Black K. L., Martin N. A., et al. Treatment of aglioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg. Focus 2000; 9: 1–5
   Google Scholar
• Yu J. S., Wheeler C. J., Zelter P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Reidinger M. S., Zhang W., Prins R. M., Black K. L. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res. 2001; 61: 842–847, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Reidinger M. S., Zhang W., Prins R. M., Black K. L. Dendritic cell immunotherapy for patients with Glioblastoma multiforme and anaplastic astrocytoma. Proc. Am. Assoc. Cancer Res. 2001; 42, Abstract 1478
   Google Scholar
• Okada H., Pollack I. F., Lieberman F., Lunsford L. D., Kondziolka D., Schiff D., Attanucci J., Edington H., Chambers W., Kalinski P., Kinzler D., Whiteside T., Elder E., Potter D. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum. Gene Ther. 2001; 12: 575–595, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 2001; 50: 337–344, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer 2003; 89: 1172–1179, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T. B., Paragnik L., Kandemir A., Lee P. P., Schuler G., Knop J., Enk A. H. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection. Int. J. Cancer 2001; 93: 243–251, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Skov S., Bonyhadi M., Odum N., Ledbetter J. A. IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells. J. Immunol. 2000; 164: 3500–3505, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dallal R. M., Lotze M. T. The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 2000; 12: 583–588, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Valone F. H., Small E., MacKenzie M., Burch P., Lacy M., Peshwa M. V., Laus R. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001; 7(suppl 2)S53–S61, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Brasel K., McKenna H. J., Morrissey P. J., Charrier K., Morris A. E., Lee C. C., Williams D. E., Lyman S. D. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996; 88: 2004, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maraskovsky E., Brasel K., Teepe M., Roux E. R., Lyman S. D., Shortman K., McKenna H. J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 1996; 184: 1953, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Daro E., Pulendran B., Brasel K., Teepe M., Pettit D., Lynch D. H., Vremec D., Robb L., Shortman K., McKenna H. J., Maliszewski C. R., Maraskovsky E. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but not CD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 2000; 165: 49, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., Caron D., Maliszewski C., Davoust J., Fay J., Palucka K. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 2000; 165: 566–572, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Parajuli P., Mosley R. L., Pisarev V., Chavez J., Ulrich A., Varney M., Singh R. K., Talmadge J. E. Flt3 ligand and granulocyte-macrophage colony-stimulation factor preferentially expand and stimulate different dendritic cell and T cell subsets. J. Exp. Hematol. 2001; 29(10)1185–1193, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Basak S. K., Harui A., Stolina M., Sharma S., Mitani K., Dubinett S. M., Roth M. D. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002; 99: 2869–2879, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Disis M. L., Rinn K., Knuston L., Davis D., Caron D., dela Rosa C., Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002; 99: 2845–2850, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parajuli P., Vladimir P., Sublet J., Steffel A., Varney M., Singh R., LaFace D., Talmadge J. E. Immunization with wild-type p53 gene sequences co-administered with Flt3 ligand induces an antigen-specific type 1 T cell response. Cancer Res. 2001; 61(22)8227–8234, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wallenfriedman M. A., Conrad J. A., DelaBarre L., Graupman P. C., Lee G., Garwood M., Gregerson D. S., Jean W. C., Hall W. A., Low W. C. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J. Neurosurg. 1999; 90: 1064–1071, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Plautz G. E., Barnet G. H., Miller D. W., Cohen B. H., Prayson R. A., Krauss J. C., Luciano M., Kangisser D. B., Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 1998; 89: 42–51, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sloan A. E., Dansey R., Zamarano L., Barger G., Hamm C., Diaz F., Baynes R., Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stmulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus 2000; 9(6)1–8, A 9
   Google Scholar
• Phan G. Q., Wang E., Marincola F. M. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin. Biol. Ther. 2001; 1: 511–523, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Garrido F., Algarra I. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 2001; 83: 117–158, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tait B. D. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Hum. Immunol. 2000; 61: 158–165, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Antel J. P., McCrea E., Ladiwala U., Qin Y. F., Becher B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J. Immunol. 1998; 160: 1606–1611, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Saeterdal I., thorStraten P., Myklebust J. H., Kirkin A. F., Gjertsen M. K., Gaudernack G. Generation and characterization of gp100 peptide-specific NK-T cell clones. Int. J. Cancer 1998; 75: 794–803, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lopez R. D., Waller E. K., Lu P. H., Negrin R. S. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol. Immunother. 2001; 49: 629–640, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Crowe N. Y., Hayakawa Y., Takeda K., Yagita H., Godfrey D. NK-T cells—conductors of tumor immunity?. Cur. Opin. Immunol. 2002; 14: 165–171, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar